Tislelizumab + Pamiparib for Cancer
Trial Summary
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. It seems that you may continue with treatments from the parent study, but it's best to discuss your specific situation with the study team.
What data supports the effectiveness of the drug combination of Tislelizumab and Pamiparib for cancer?
Research shows that combining pamiparib, a drug that helps repair damaged DNA, with tislelizumab, a drug that helps the immune system fight cancer, has shown antitumor activity in patients with advanced solid tumors. Additionally, similar drugs like atezolizumab have been effective in treating certain types of breast cancer, suggesting potential benefits of this combination.12345
Is the combination of Tislelizumab and Pamiparib safe for humans?
What makes the drug combination of pamiparib and tislelizumab unique for treating advanced solid tumors?
The combination of pamiparib, a PARP inhibitor that helps repair damaged DNA in cancer cells, and tislelizumab, an immune checkpoint inhibitor that helps the immune system attack cancer cells, is unique because it targets both the cancer cells' DNA repair mechanisms and the immune system's ability to recognize and destroy cancer cells, offering a novel approach for treating advanced solid tumors.12348
What is the purpose of this trial?
This is an open-label, multicenter, extension study to evaluate the long-term safety and efficacy of BeiGene investigational drugs in participants with advanced malignancies who participated in a prior BeiGene-sponsored clinical study (parent study).
Research Team
Study Director
Principal Investigator
BeiGene
Eligibility Criteria
This trial is for patients with advanced malignancies who were previously in a BeiGene study and may benefit from continued treatment. It's not for those who had severe side effects, recent serious infections, or used other cancer treatments between studies. Pregnant women and individuals with life-threatening conditions are also excluded.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive Tislelizumab, Pamiparib, and other investigational agents as part of the extension study
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Pamiparib
- Tislelizumab
Pamiparib is already approved in China for the following indications:
- Ovarian cancer
Find a Clinic Near You
Who Is Running the Clinical Trial?
BeiGene
Lead Sponsor